• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.

作者信息

Chakraborty Rajshekhar, Cheruvalath Heloise, Patwari Anannya, Szabo Aniko, Schinke Carolina, Dhakal Binod, Lentzsch Suzanne, D'Souza Anita, Mohyuddin Ghulam Rehman, Julian Kelley, Midha Shonali, Costello Patrick, Kaiser Martin, Hing Melissa Ng Liet, Harrison Simon J, Cliff Edward R Scheffer, Mohan Meera

机构信息

Columbia University Irving Medical Center, New York, NY, USA.

Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.

DOI:10.1038/s41408-024-01114-7
PMID:39134535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11319778/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5731/11319778/365851e70e40/41408_2024_1114_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5731/11319778/2b444470be3d/41408_2024_1114_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5731/11319778/365851e70e40/41408_2024_1114_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5731/11319778/2b444470be3d/41408_2024_1114_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5731/11319778/365851e70e40/41408_2024_1114_Fig2_HTML.jpg

相似文献

1
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.复发/难治性骨髓瘤患者接受有限疗程双特异性抗体治疗后的持续缓解
Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.
2
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.特卡昔单抗，一种 B 细胞成熟抗原 × CD3 双特异性抗体，用于治疗复发或难治性多发性骨髓瘤（MajesTEC-1）：一项多中心、开放标签、单臂、1 期研究。
Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.
3
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.复发/难治性多发性骨髓瘤的新兴疗法：嵌合抗原受体T细胞疗法及其他。
J Hematol Oncol. 2021 Jul 23;14(1):115. doi: 10.1186/s13045-021-01109-y.
4
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.用莫苏奈妥珠单抗治疗复发/难治性毛细胞白血病，莫苏奈妥珠单抗是一种双特异性抗体。
Leuk Lymphoma. 2024 May;65(5):684-687. doi: 10.1080/10428194.2024.2304026. Epub 2024 Jan 22.
5
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
6
Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.抗体药物偶联物和双特异性 T 细胞衔接器治疗多发性骨髓瘤新时代的曙光：文献系统评价。
Ann Hematol. 2021 Sep;100(9):2155-2172. doi: 10.1007/s00277-021-04599-5. Epub 2021 Jul 27.
7
Antibody treatment in multiple myeloma.多发性骨髓瘤的抗体治疗。
Clin Adv Hematol Oncol. 2021 Mar;19(3):166-174.
8
Bispecific antibody targets and therapies in multiple myeloma.双特异性抗体在多发性骨髓瘤中的靶点和治疗方法。
Front Immunol. 2024 Oct 10;15:1424925. doi: 10.3389/fimmu.2024.1424925. eCollection 2024.
9
Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.嵌合抗原受体 T 细胞、双特异性抗体和抗体药物偶联物治疗多发性骨髓瘤：最新进展。
Am J Hematol. 2022 Jan 1;97(1):99-118. doi: 10.1002/ajh.26379. Epub 2021 Nov 10.
10
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.用于多发性骨髓瘤的双特异性抗体：最新进展及提高其疗效的策略
Front Biosci (Landmark Ed). 2024 Jun 17;29(6):216. doi: 10.31083/j.fbl2906216.

引用本文的文献

1
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.多发性骨髓瘤中针对BCMA的双特异性抗体和CAR T细胞疗法的耐药机制
Cells. 2025 Jul 15;14(14):1077. doi: 10.3390/cells14141077.
2
From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.从分子精准到临床实践：血液系统恶性肿瘤中双特异性和三特异性抗体的综合综述
Int J Mol Sci. 2025 Jun 1;26(11):5319. doi: 10.3390/ijms26115319.
3
An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma.

本文引用的文献

1
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.在MajesTEC-1研究中接受替西妥单抗治疗复发/难治性多发性骨髓瘤患者的感染发生率、发生时间及管理
Cancer. 2024 Mar 15;130(6):886-900. doi: 10.1002/cncr.35107. Epub 2023 Nov 14.
2
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.新诊断多发性骨髓瘤（MASTER）中基于微小残留病灶反应的适应性治疗：多中心、单臂、2 期试验的最终报告。
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
3
一种用于多发性骨髓瘤治疗和诊断的抗BCMA亲合体亲和蛋白。
Int J Mol Sci. 2025 May 28;26(11):5186. doi: 10.3390/ijms26115186.
4
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.双特异性抗体和嵌合抗原受体T细胞疗法在多发性骨髓瘤中的应用：患者的合理选择与治疗顺序
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025045. doi: 10.4084/MJHID.2025.045. eCollection 2025.
5
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.静脉注射免疫球蛋白（IVIG）补充对接受靶向BCMA双特异性抗体治疗的多发性骨髓瘤患者无感染生存期的影响。
Blood Cancer J. 2025 Apr 23;15(1):74. doi: 10.1038/s41408-025-01282-0.
6
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.多发性骨髓瘤（MM）中替西帕单抗和他喹莫单抗的真实世界治疗模式：609例患者的经验
Blood Cancer J. 2025 Apr 8;15(1):61. doi: 10.1038/s41408-025-01254-4.
7
Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.塔洛夸单抗治疗多发性骨髓瘤的前景：安全性、疗效及治疗地位
Cancer Manag Res. 2025 Apr 3;17:743-756. doi: 10.2147/CMAR.S441550. eCollection 2025.
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
BCMA 或 GPRC5D 靶向免疫疗法治疗多发性骨髓瘤中抗原逃逸的机制。
Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31.
4
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.复发/难治性多发性骨髓瘤患者中，针对 BCMA 和 GPRC5D 的双特异性抗体（bsAb）治疗的感染谱变化。
Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590.
5
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Elranatamab 治疗复发/难治性多发性骨髓瘤：MagnetisMM-3 期临床试验结果。
Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.
6
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.多发性骨髓瘤中双特异性抗体相关感染：系统评价和荟萃分析。
Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539.
7
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.认识到双特异性抗体治疗多发性骨髓瘤试验中的感染风险。
J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30.
8
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
9
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.塔奎单抗，一种用于多发性骨髓瘤的靶向 GPRC5D 的 T 细胞双特异性抗体。
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
10
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.西达基奥仑赛治疗既往接受过其他 BCMA 靶向药物治疗的进展性多发性骨髓瘤患者的疗效和安全性。
Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526.